HUE052441T2 - Intranazális készítmények neurológiai és neurodegeneratív betegségekre és zavarokra - Google Patents
Intranazális készítmények neurológiai és neurodegeneratív betegségekre és zavarokraInfo
- Publication number
- HUE052441T2 HUE052441T2 HUE15848100A HUE15848100A HUE052441T2 HU E052441 T2 HUE052441 T2 HU E052441T2 HU E15848100 A HUE15848100 A HU E15848100A HU E15848100 A HUE15848100 A HU E15848100A HU E052441 T2 HUE052441 T2 HU E052441T2
- Authority
- HU
- Hungary
- Prior art keywords
- neurological
- disorders
- neurodegenerative diseases
- intranasal preparations
- intranasal
- Prior art date
Links
- 208000012902 Nervous system disease Diseases 0.000 title 1
- 208000025966 Neurological disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 230000004770 neurodegeneration Effects 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 230000000926 neurological effect Effects 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2014903944A AU2014903944A0 (en) | 2014-10-03 | Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE052441T2 true HUE052441T2 (hu) | 2021-04-28 |
Family
ID=55629161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE15848100A HUE052441T2 (hu) | 2014-10-03 | 2015-09-30 | Intranazális készítmények neurológiai és neurodegeneratív betegségekre és zavarokra |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10471040B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3200828B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2017530195A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015327762C1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2961936C (cg-RX-API-DMAC7.html) |
| DK (1) | DK3200828T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2822562T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE052441T2 (cg-RX-API-DMAC7.html) |
| PL (1) | PL3200828T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3200828T (cg-RX-API-DMAC7.html) |
| SM (1) | SMT202000576T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016049700A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016049700A1 (en) * | 2014-10-03 | 2016-04-07 | Lachesis Biosciences Pty Ltd | Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders |
| KR102653545B1 (ko) * | 2017-02-02 | 2024-04-04 | 오토라눔 아게 | 베타히스틴을 포함하는 비강내 조성물 |
| AU2021297549A1 (en) * | 2020-06-25 | 2023-01-05 | Lachesis Biosciences Limited | Methods of treating or preventing organophosphorus poisoning |
| CA3193558A1 (en) * | 2020-10-01 | 2022-04-07 | Lyra Therapeutics, Inc. | Osmotic drug delivery implants |
| CN115919767B (zh) * | 2022-10-13 | 2023-08-11 | 暨南大学 | 卡巴拉汀鼻喷雾剂及其制备方法 |
| CN119523898A (zh) * | 2024-12-02 | 2025-02-28 | 肇庆学院 | 多靶点药物的经鼻给药制剂及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR5733M (cg-RX-API-DMAC7.html) | 1966-09-27 | 1968-01-22 | ||
| US4806543A (en) | 1986-11-25 | 1989-02-21 | Board Of Trustees Of The Leland Stanford Junior University | Method and compositions for reducing neurotoxic injury |
| FR2722989B1 (fr) | 1994-07-29 | 1997-05-30 | Synthelabo | Utilisation de l'ifenprodil et de ses enantiomeres pour la preparation de medicaments utiles dans le traitement des neuropathies peripheriques et des maladies neurodegeneratives centrales |
| US6558560B2 (en) * | 2001-07-27 | 2003-05-06 | Hewlett-Packard Company | Method for the fabrication of electrical contacts |
| WO2004034963A2 (en) * | 2002-05-17 | 2004-04-29 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
| US20040254146A1 (en) * | 2002-05-21 | 2004-12-16 | Nastech Pharmaceutical Company Inc. | Carboxylate salts of galantamine and their pharmaceutical use |
| US20030225031A1 (en) * | 2002-05-21 | 2003-12-04 | Quay Steven C. | Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid |
| CA2581816A1 (en) * | 2004-09-27 | 2006-04-06 | Sigmoid Biotechnologies Limited | Microcapsules comprising a methylxanthine and a corticosteroid |
| US8187570B1 (en) * | 2005-01-04 | 2012-05-29 | Gp Medical, Inc. | Nanoparticles for protein drug delivery |
| RU2007140348A (ru) * | 2005-04-06 | 2009-05-20 | Адамас Фармасьютикалс, Инк. (Us) | Способы и композиции для лечения заболеваний цнс |
| ATE544444T1 (de) * | 2005-10-11 | 2012-02-15 | Yissum Res Dev Co | Zusammensetzungen für die nasale abgabe |
| US8911751B2 (en) * | 2005-10-11 | 2014-12-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions for nasal delivery |
| AU2007212586A1 (en) * | 2006-02-03 | 2007-08-16 | Avanir Pharmaceuticals | Pharmaceutical compositions for treating depression, anxiety and neurodegenerative disorders |
| US20070202055A1 (en) * | 2006-02-09 | 2007-08-30 | Julianne Berry | Pharmaceutical Formulations |
| CN101784287B (zh) * | 2007-06-26 | 2013-04-24 | 若素制药株式会社 | 水性组合物 |
| FR2931677B1 (fr) * | 2008-06-02 | 2010-08-20 | Sanofi Aventis | Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs |
| DK3029039T3 (en) | 2010-05-17 | 2017-12-04 | Forum Pharmaceuticals Inc | PHARMACEUTICAL FORMS CONTAINING CRYSTALLINIC FORMS OF (R) -7-CHLOR-N- (QUINUCLIDIN-3-YL) BENZO (B) THIOPHEN-2-CARBOXAMIDE HYDROCHLORIDE MONOHYDRATE |
| US8673338B2 (en) * | 2011-07-29 | 2014-03-18 | Massachusetts Eye And Ear Infirmary | Methods of delivering pharmaceutical agents |
| WO2016049700A1 (en) * | 2014-10-03 | 2016-04-07 | Lachesis Biosciences Pty Ltd | Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders |
-
2015
- 2015-09-30 WO PCT/AU2015/050591 patent/WO2016049700A1/en not_active Ceased
- 2015-09-30 AU AU2015327762A patent/AU2015327762C1/en active Active
- 2015-09-30 PT PT158481002T patent/PT3200828T/pt unknown
- 2015-09-30 JP JP2017536991A patent/JP2017530195A/ja active Pending
- 2015-09-30 PL PL15848100T patent/PL3200828T3/pl unknown
- 2015-09-30 DK DK15848100.2T patent/DK3200828T3/da active
- 2015-09-30 HU HUE15848100A patent/HUE052441T2/hu unknown
- 2015-09-30 SM SM20200576T patent/SMT202000576T1/it unknown
- 2015-09-30 CA CA2961936A patent/CA2961936C/en active Active
- 2015-09-30 US US15/516,233 patent/US10471040B2/en active Active
- 2015-09-30 EP EP15848100.2A patent/EP3200828B1/en active Active
- 2015-09-30 ES ES15848100T patent/ES2822562T3/es active Active
-
2019
- 2019-09-13 US US16/569,986 patent/US10933045B2/en active Active
-
2020
- 2020-03-04 JP JP2020036966A patent/JP7357571B2/ja active Active
-
2021
- 2021-01-27 US US17/160,009 patent/US11911360B2/en active Active
- 2021-10-20 JP JP2021171712A patent/JP2022003100A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2961936A1 (en) | 2016-04-07 |
| WO2016049700A1 (en) | 2016-04-07 |
| ES2822562T3 (es) | 2021-05-04 |
| JP2020090547A (ja) | 2020-06-11 |
| US10471040B2 (en) | 2019-11-12 |
| AU2015327762A1 (en) | 2017-04-20 |
| US20170239209A1 (en) | 2017-08-24 |
| JP2022003100A (ja) | 2022-01-11 |
| EP3200828B1 (en) | 2020-08-12 |
| SMT202000576T1 (it) | 2020-11-10 |
| PL3200828T3 (pl) | 2021-01-25 |
| JP7357571B2 (ja) | 2023-10-06 |
| EP3200828A4 (en) | 2018-04-25 |
| US10933045B2 (en) | 2021-03-02 |
| CA2961936C (en) | 2023-03-14 |
| JP2017530195A (ja) | 2017-10-12 |
| US20200078331A1 (en) | 2020-03-12 |
| AU2015327762B2 (en) | 2020-06-25 |
| DK3200828T3 (da) | 2020-10-12 |
| US20210145789A1 (en) | 2021-05-20 |
| AU2015327762C1 (en) | 2020-10-22 |
| US11911360B2 (en) | 2024-02-27 |
| EP3200828A1 (en) | 2017-08-09 |
| PT3200828T (pt) | 2020-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279930A (en) | Gene therapies for lysosomal disorders | |
| HUE049014T2 (hu) | Készítmények és módszerek a központi idegrendszer rendellenességeinek kezelésére | |
| IL248732B (en) | Compounds for the treatment of ophthalmological diseases and disorders | |
| ME03454B (me) | Terapeutski agensi za neurodegenerativne bolesti | |
| HUE051488T2 (hu) | Készítmények és eljárások központi idegrendszeri rendellenességek kezelésére | |
| EP3227330A4 (en) | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases | |
| PL3177723T3 (pl) | Aptamery do zastosowania przeciwko chorobom związanym z autoprzeciwciałem | |
| IL252696A0 (en) | protein production | |
| EP3157631A4 (en) | Neurodegenerative disease treatment | |
| GB201420986D0 (en) | Neurodegenerative disorders | |
| GB201516905D0 (en) | Treatment of Neurodegenerative diseases | |
| DK3122763T3 (da) | Antimikrobielle peptiddendrimerer | |
| HUE052441T2 (hu) | Intranazális készítmények neurológiai és neurodegeneratív betegségekre és zavarokra | |
| DK3164716T3 (da) | Fremgangsmåde til diagnosticering af neurodegenerative sygdomme | |
| HUE058705T2 (hu) | Herbicidtolerancia-gének és eljárások ezek alkalmazására | |
| PT3124621T (pt) | Marcadores mitocondriais de doenças neurodegenerativas | |
| GB201513845D0 (en) | Neurodegenerative disorders | |
| ZA201902689B (en) | Therapeutic protein | |
| HUE053974T2 (hu) | Szemészeti gyógyászati készítmény | |
| GB201701455D0 (en) | Neurodegenerative disorders | |
| GB201713743D0 (en) | Ophthalmic probes | |
| PL3903774T3 (pl) | N,n-bis-2-merkaptoetyloizoftalamid do leczenia chorób neurodegeneracyjnych | |
| GB201407132D0 (en) | Marker for neurodegenerative disorders | |
| HK40092417A (zh) | 用於治疗眼科疾病和障碍的化合物 | |
| GB201616715D0 (en) | Therapeutic protein |